Optimizing downstream purification of high-quality plasmid DNA for gene therapy and vaccine production

Becerra, Alejandro; Buyel, Johannes F.

doi:10.18609/cgti.2021.162

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[72,79,87,88] AEC is performed in five cycles per batch with a binding capacity of 10 g⋅L −1 . [73,85,88] After loading, the column is equilibrated with a Tris-EDTA buffer with no salt and pH 7.2, and then a Tris-EDTA buffer with NaCl 0.5 M is employed for the washing step. [73,83] RNA is eluted with a buffer gradient starting with 0.5 M NaCl, followed by plasmid elution in a buffer gradient ending in 1.0 M NaCl.…”

Section: Purificationmentioning

confidence: 99%

“…[73,76] The precipitated material containing cell debris and most of the gDNA, high molecular weight RNA, and proteins are removed by centrifugation for 30 min. [83,85] The pDNA supernatant is further clarified through a 0.22 µm depth filter. [75,76,85] To minimize plasmid losses, the depth filter is flushed with a Tris-EDTA buffer.…”

Section: Cell Cultivationmentioning

confidence: 99%

“…[83,85] The pDNA supernatant is further clarified through a 0.22 µm depth filter. [75,76,85] To minimize plasmid losses, the depth filter is flushed with a Tris-EDTA buffer. [73] After the cell debris and most of the gDNA and proteins are removed, the majority of impurities in the process are now RNA, gDNA fragments, proteins, endotoxins and plasmid variants.…”

Section: Cell Cultivationmentioning

confidence: 99%

See 2 more Smart Citations

Uncertainty quantification for gene delivery methods: A roadmap for pDNA manufacturing from phase I clinical trials to commercialization

Triantafyllou,

Sarkis,

Krassakopoulou

et al. 2023

Biotechnology Journal

View full text Add to dashboard Cite

The fast‐growing interest in cell and gene therapy (C&GT) products has led to a growing demand for the production of plasmid DNA (pDNA) and viral vectors for clinical and commercial use. Manufacturers, regulators, and suppliers need to develop strategies for establishing robust and agile supply chains in the otherwise empirical field of C&GT. A model‐based methodology that has great potential to support the wider adoption of C&GT is presented, by ensuring efficient timelines, scalability, and cost‐effectiveness in the production of key raw materials. Specifically, key process and economic parameters are identified for (1) the production of pDNA for the forward‐looking scenario of non‐viral‐based Chimeric Antigen Receptor (CAR) T‐cell therapies from clinical (200 doses) to commercial (40,000 doses) scale and (2) the commercial (40,000 doses) production of pDNA and lentiviral vectors for the current state‐of‐the‐art viral vector‐based CAR T‐cell therapies. By applying a systematic global sensitivity analysis, we quantify uncertainty in the manufacturing process and apportion it to key process and economic parameters, highlighting cost drivers and limitations that steer decision‐making. The results underline the cost‐efficiency and operational flexibility of non‐viral‐based therapies in the overall C&GT supply chain, as well as the importance of economies‐of‐scale in the production of pDNA.

show abstract